Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial
Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Amgen is running a phase 3 trial to compare its eye drug ABP 938 8 mg with EYLEA HD in people with wet age-related macular degeneration. The official goal is to show similar vision gains, safety, and immune response, which could support a lower-cost rival to a key blockbuster therapy.
The study tests two intravitreal injections, ABP 938 8 mg and aflibercept 8 mg, both given directly into the eye. The aim is to see if Amgen’s drug can match the vision benefits and treatment schedule of EYLEA HD while maintaining a similar safety profile.
The trial uses a randomized, parallel-group design so patients are assigned by chance to one of the two drugs. It is double-masked, meaning neither patients nor doctors know which drug is used, and the main purpose is to treat disease while comparing outcomes head to head.
The study began after first submission on 22 May 2026 and is now in recruiting status, so enrollment and dosing are underway. The latest update on 10 June 2026 signals active trial management, but primary and final completion dates have not yet been reported to investors.
If ABP 938 proves similar to EYLEA HD, Amgen could gain a foothold in the highly profitable retinal disease market and pressure Regeneron and Bayer on price. The update may support a modestly positive tone for AMGN, while adding competitive risk for incumbents that rely on EYLEA franchise revenue.
The study remains ongoing and recently updated, with further details and any future changes available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.
